PRESS RELEASE published on 06/03/2024 at 08:00, 1 year 11 months ago AVENANT AU CONTRAT DE FINANCEMENT OBLIGATAIRE CONVERTIBLE : REECHELONNEMENT DU REMBOURSEMENT SUR TROIS ANS MUNIC signe un avenant au contrat de financement obligataire convertible pour un remboursement progressif sur les exercices 2024, 2025 et 2026, avec un horizon de trésorerie étendu. Engagement des actionnaires. Développement de la plateforme EKKO MUNIC Avenant Remboursement Progressif Trésorerie Étendue EKKO
PRESS RELEASE published on 06/03/2024 at 07:30, 1 year 11 months ago STS Group AG continues positive development with significant increase in sales revenue and earnings in the first quarter of 2024 STS Group AG reports a significant increase in sales revenue and earnings in the first quarter of 2024 despite economic challenges. Full-year guidance reaffirmed Sales Revenue Earnings First Quarter 2024 STS Group AG Full-year Guidance
PRESS RELEASE published on 06/03/2024 at 07:30, 1 year 11 months ago Mutares has successfully completed the acquisition of FSL Ladenbau GmbH Mutares SE & Co. KGaA successfully completes acquisition of FSL Ladenbau GmbH, a leading shopfitting provider in Northern Germany, strengthening Ganter Group with synergies and EUR 15 million in planned revenues for 2024 Acquisition Mutares SE & Co. KGaA FSL Ladenbau GmbH Ganter Group Shopfitting Provider
PRESS RELEASE published on 06/03/2024 at 07:30, 1 year 11 months ago Vallourec : André Lacerda est nommé Directeur Amérique du Sud (Activités Tubes) Vallourec nomme André Lacerda Directeur Amérique du Sud pour les activités Tubes. Expérience internationale solide et expertise en croissance et transformation Croissance Vallourec André Lacerda Directeur Amérique Du Sud Activités Tubes
PRESS RELEASE published on 06/03/2024 at 07:30, 1 year 11 months ago Transgene – Premier patient inclus dans la partie Phase II de l’étude randomisée de Phase I/II de son actif phare TG4050, un vaccin thérapeutique individualisé évalué dans les cancers de la tête et du cou Transgene annonce l'inclusion du premier patient dans la partie Phase II de l'étude randomisée de Phase I/II pour son vaccin TG4050 dans les cancers de la tête et du cou. Démarrage de la sélection des patients pour cette étude internationale Cancer De La Tête Et Du Cou Étude Clinique Transgene Vaccin Thérapeutique Néoantigènes
PRESS RELEASE published on 06/03/2024 at 07:30, 1 year 11 months ago Informations privilégiées / Autres communiqués GenSight Biologics nomme William Monteith à son Conseil d'administration. Monteith apportera son expertise en fabrication de thérapies géniques pour soutenir les progrès de l'entreprise Conseil D'administration Fabrication GenSight Biologics Thérapies Géniques William Monteith
PRESS RELEASE published on 06/03/2024 at 07:30, 1 year 11 months ago Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer Transgene enrolls first patient in Phase II of randomized Phase I/II trial for cancer vaccine TG4050 in head and neck cancer, with completion expected in Q4 2025 Phase II Trial Head And Neck Cancer Cancer Vaccine Transgene TG4050
PRESS RELEASE published on 06/03/2024 at 07:30, 1 year 11 months ago Number of voting rights as of May 31, 2024 Nicox SA monthly publication of the number of shares and voting rights. Details on market, ISIN code, and company's lead programs Voting Rights Shares Ophthalmology Monthly Publication Nicox SA
PRESS RELEASE published on 06/03/2024 at 07:30, 1 year 11 months ago Vallourec: Andre Lacerda Appointed Senior Vice President of South America (Tubes Activities) Vallourec appoints Andre Lacerda as Senior Vice President of South America for Tubes segment, bringing extensive international experience and market knowledge South America Senior Vice President Vallourec André Lacerda Tubes
PRESS RELEASE published on 06/03/2024 at 07:00, 1 year 11 months ago Relief Therapeutics Announces Executive Changes Relief Therapeutics announces executive changes as interim CEO Michelle Lock completes her mandate and transitions out, along with other key executives. Board to review management for optimal results Executive Changes Biopharmaceutical Relief Therapeutics Rare Diseases Management Review
Published on 05/02/2026 at 21:00, 15 hours 26 minutes ago GECC Subsidiary Provides Update on its Lawsuit for Damages Against the Lender of the Atmosphere Project
Published on 05/02/2026 at 01:30, 1 day 10 hours ago Uraniumx Reports Strong Financial Position Ahead of Spring Drill Program
Published on 05/02/2026 at 00:50, 1 day 11 hours ago CoTec Announces Annual Stock Option, Restricted Share Unit And Deferred Share Unit Grants
Published on 05/02/2026 at 00:00, 1 day 12 hours ago Redwood AI Announces Enhanced AI Models, Increasing Evaluated Chemical Reactions Following Preliminary Results from UBC Collaboration
Published on 05/02/2026 at 00:00, 1 day 12 hours ago Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
Published on 05/03/2026 at 04:45, 7 hours 41 minutes ago GWM Unveils World-Class Safety & Testing Facilities: Safety Built on Data, Not Hype
Published on 05/02/2026 at 15:35, 20 hours 51 minutes ago Ecuador's banana sector renews labor agreement, with jobs meeting global standards
Published on 05/01/2026 at 19:23, 1 day 17 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/30/2026 at 21:21, 2 days 15 hours ago CP -Mise à disposition du rapport financier annuel 2025
Published on 04/30/2026 at 20:00, 2 days 16 hours ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 20:00, 2 days 16 hours ago AMA Corp PLC : Résultats 2025 & Chiffre d'affaires du 1er trimestre 2026
Published on 04/30/2026 at 19:16, 2 days 17 hours ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:16, 2 days 17 hours ago AXA annonce les résultats de son Assemblée Générale